Browse the corpus

Plasmodium knowlesi, a zoonotic parasite of long-tailed and pig-tailed macaques, is an important cause of human malaria in Southeast Asia [1–3]. In some areas in this region, incidence has increased alongside the near-elimination of falciparum and vivax malaria, with P. knowlesi now the most common cause of malaria in Malaysia [4] and parts of western Indonesia [5–7]. Risk of severe disease from P. knowlesi is at least as high as from Plasmodium falciparum in coendemic areas [8, 9], occurring in 6%–9% of symptomatic adults [10, 11], and fatal cases have been reported [4, 9, 11–16]. Independent risk factors for severe malaria include older age and increasing parasitemia [10, 17]; however, risk factors for death are poorly defined. To delineate factors associated with knowlesi malaria mortality, we reviewed malaria deaths in Sabah, Malaysia, from 2015 to 2017, and conducted a systematic review of all previously reported fatal cases. Plasmodium knowlesi case fatality rates (CFRs) in Sabah during 2010–2017 were calculated using previously reported mortality and incidence data [4, 18]. METHODS Case Series: Malaria Deaths, Sabah, 2015–2017 All malaria deaths in Sabah from 2015–2017 were identified from the Sabah Department of Health. In Sabah, hospital admission and notification to the Department of Health are mandatory for all malaria cases, as is reporting of deaths. Since 2015 it has also been mandatory for a blood sample from all malaria cases to be sent to the state public health laboratory for Plasmodium species confirmation by polymerase chain reaction (PCR).

admission and notification to the Department of Health are mandatory for all malaria cases, as is reporting of deaths. Since 2015 it has also been mandatory for a blood sample from all malaria cases to be sent to the state public health laboratory for Plasmodium species confirmation by polymerase chain reaction (PCR). Case notes were retrieved from relevant health facilities and reviewed. Approval was obtained from the ethics committees of the Ministry of Health, Malaysia, and the Menzies School of Health Research, Australia. Systematic Review of the Literature We searched Medline, PubMed, and Science Direct for articles published up to August 2018, containing the words “knowlesi AND death,” “knowlesi AND fatality,” or “knowlesi AND outcome,” including synonyms and Medical Subject Heading terms. Relevant references cited within these articles were also reviewed. Case Fatality Rates Plasmodium knowlesi CFRs in Sabah were calculated from 2010 to 2017 using malaria incidence and fatality data from the Sabah Department of Health [4, 18]. Male and female CFRs were compared using Fisher exact test. Logistic regression was used to evaluate age and sex as independent risk factors for death.

Case Fatality Rates Plasmodium knowlesi CFRs in Sabah were calculated from 2010 to 2017 using malaria incidence and fatality data from the Sabah Department of Health [4, 18]. Male and female CFRs were compared using Fisher exact test. Logistic regression was used to evaluate age and sex as independent risk factors for death. RESULTS Case Series: Malaria Deaths, Sabah, 2015–2017 Six malaria deaths were reported to the Sabah Department of Health during 2015–2017, all confirmed by PCR as P. knowlesi monoinfections. Baseline demographic and clinical details are shown in Tables 1 and 2, laboratory details in Table 3, and severity criteria in Table 4 (cases G1–G6). The median age was 40 (range, 23–58) years. Four (67%) cases were male; 3 (50%) were non-Malaysian citizens. Three (50%) cases had significant cardiovascular-metabolic comorbidities (severe mitral stenosis, ischemic heart disease, and morbid obesity with heart failure, respectively), and one other was pregnant. Median fever duration was 8 (range, 4–14) days. Five had severe malaria on presentation; intravenous (IV) artesunate was administered upon hospitalization in only 2 cases, with artesunate unavailable in 2 cases. Initial hospital microscopy correctly reported P. knowlesi in 2 (33%) cases; the others were reported as Plasmodium malariae (n = 2) and P. falciparum (n = 2). Median time from admission to death was 29 (range, 7–144) hours. Table 1. Article Summary, Demographics, and Treatment

RESULTS Case Series: Malaria Deaths, Sabah, 2015–2017 Six malaria deaths were reported to the Sabah Department of Health during 2015–2017, all confirmed by PCR as P. knowlesi monoinfections. Baseline demographic and clinical details are shown in Tables 1 and 2, laboratory details in Table 3, and severity criteria in Table 4 (cases G1–G6). The median age was 40 (range, 23–58) years. Four (67%) cases were male; 3 (50%) were non-Malaysian citizens. Three (50%) cases had significant cardiovascular-metabolic comorbidities (severe mitral stenosis, ischemic heart disease, and morbid obesity with heart failure, respectively), and one other was pregnant. Median fever duration was 8 (range, 4–14) days. Five had severe malaria on presentation; intravenous (IV) artesunate was administered upon hospitalization in only 2 cases, with artesunate unavailable in 2 cases. Initial hospital microscopy correctly reported P. knowlesi in 2 (33%) cases; the others were reported as Plasmodium malariae (n = 2) and P. falciparum (n = 2). Median time from admission to death was 29 (range, 7–144) hours. Table 1. Article Summary, Demographics, and Treatment Author Year Published (Period) Location Case Sex Age, y Fever, d Malaysian Citizen Correct Diagnosisa Severe Diagnosisb Initial Therapy IV Therapyc Time to Death, h Cox-Singh et al [14] 2008 (2001–2006) Sarawak A1 F 66 3 NR N N N CQ, SP 35 A2 M 69 3 NR Y Y NR Q 141 A3 M 39 3 NR Y Y N CQ, SP 5 A4 M 40 7 NR Y Y Y CQ, SP, PQ, Q 316 Daneshvar et al [11] 2009 (2006–2008) Sarawak B1 F 68 NR NR NR Y Y Q 6 B2 F 36 NR NR NR Y Y Q 24 Cox-Singh et al [16] 2010 Sarawak C1 M 40 5 Y N N N None 2 William et al [9] 2011 (2007–2009) Sabah D1 F 76 NR Y NR Y Y Q 96 D2 F 65 5 Y NR Y Y Q 96 D3 M 57 7 Y NR Y Y Art 48 D4 F 84 5 Y NR Y Y Q 96 D5 M 56 5 Y NR Y Y Q <24 D6 M 46 7 Y NR Y Y Q 24 Rajahram et al [12] 2013 (2010–2011) Sabah E1 M 71 7 NR Y N Y Q, PQ, CQ, D 1 E2 M 65 2 NR N N N CQ 75 E3 M 51 4 NR Y Y Y Art 16 E4 M 50 7 NR Y Y N CQ 56 E5 F 49 4 NR Y N N CQ, PQ 63 E6d F 36 7 NR Y N N SP, PQ 84 Rajahram et ale [4] 2016 (2012–2014) Sabah F1 M 31 7 Y N N Y Art, D 216 F2f F 71 5 Y Y Y Y Art, D 12 F3 F 61 7 Y Y Y Y Art 7 F4 M 56 3 N Y Y Y Art, D 41 F5 F 57 7 N Y N Y Art, PQ, CQ NR F6 M 73 7 Y Y NR Y Art, D 72 F7 F 62 6 Y Y N N A-M 23 Newly reported 2018 (2015–2017) Sabah G1g F 32 14 Y Y Y N A-L, Dh 10.5 G2i M 50 7 N Y Y Y Art 7 G3 F 37 4 Y N N N None 43 G4 M 42 5 N Y N N A-L 15 G5 M 32 9 Y Y Y Y Art 144 G6 M 58 9 N Y Y Yh Arth 70 Total (%) … M: 18/32 (56) 56j 6j 15/20 (75) … 19/24 (79) 20/31 (65) … 41j Abbreviations: A-L, artemether-lumefantrine; A-M, artemether-mefloquine; Art, artesunate; CQ, chloroquine; D, doxycycline; F, female; IV, intravenous; M, male; N, no; NR, not reported; PQ, primaquine; Q, quinine; SP, sulfadoxine-pyrimethamine; Y, yes.

(%) … M: 18/32 (56) 56j 6j 15/20 (75) … 19/24 (79) 20/31 (65) … 41j Abbreviations: A-L, artemether-lumefantrine; A-M, artemether-mefloquine; Art, artesunate; CQ, chloroquine; D, doxycycline; F, female; IV, intravenous; M, male; N, no; NR, not reported; PQ, primaquine; Q, quinine; SP, sulfadoxine-pyrimethamine; Y, yes. aDiagnosed as malaria at presentation. bDiagnosed as severe malaria at presentation. cInitial therapy on malaria diagnosis. d Plasmodium knowlesi–associated, gram-negative sepsis. eOne fatal case of microscopy-diagnosed “Plasmodium malariae” was described in this series, but has not been included in the review due to lack of polymerase chain reaction confirmation. fThis patient was also described in a separate case report [13]. gThirty-five weeks’ gestation at presentation. hIV therapy not available at presenting hospital. iThis patient was previously reported in a prospective observational study [10]. jValues are presented as the median. Table 3. Laboratory Features on Presentation

eOne fatal case of microscopy-diagnosed “Plasmodium malariae” was described in this series, but has not been included in the review due to lack of polymerase chain reaction confirmation. fThis patient was also described in a separate case report [13]. gThirty-five weeks’ gestation at presentation. hIV therapy not available at presenting hospital. iThis patient was previously reported in a prospective observational study [10]. jValues are presented as the median. Table 3. Laboratory Features on Presentation Case Hb, g/dL WBC, × 103 Cells/µL Plt, × 109 Cells/µL Na, mmol/L Creat, µmol/L Urea, µmol/L Bili, µmol/L AST, U/L ALT, U/L Alb, g/L HCO3, mmol/L Lac, mmol/L Speciesa Parasites/µL Blood A1 10.6 16.7 22 NR 500 61 79 122 104 24 NR NR Pm 204 800 A2 15.2 6.6 25 NR NR 26 300 163 77 15 NR NR Pm 75 000 A3 15.4 13.4 24 NR NR 19 NR NR NR NR NR NR Pm 112 000 A4 11.9 11.4 24 NR 557 25 490 87 82 28 NR NR Pm ++++ B1 NR NR NR NR 320 NR NR NR NR NR NR 17.4 NR 222 570 B2 NR NR NR NR NR NR 178 NR NR NR NR NR NR 214 000 C1 12.7 10.1 43 126 NR 34 NR 131 NR NR NR NR NR NR D1 14.6 6.1 42 129 173 29 660 110 145 28 20 NR Pm 4+ D2 12.6 20.1 26 128 492 50 103 67 85 32 17 NR Pm 4+ D3 9.4 20 35 133 819 73 397 19 230 24 10.7 NR Pm 4+ D4 10.5 9.7 34 129 239 NR NR NR NR NR NR NR Pm 2+ D5 15.4 11.9 28 128 380 NR NR NR NR NR 11 NR Pm 4+ D6 16.8 21.6 16 134 526 23 640 210 275 26 12 NR Pm 4+ E1 14.9 10.8 88 NR 1451 82 NR 42 NR NR NR NR Pf 3+ E2 14.6 4.8 58 NR NR 6 NR NR NR NR NR NR Pm 3+ E3 9.4 6.8 8 NR 578 44 146 53 28 23 14 6.4 Pm 4+ E4 10.9 7.81 3 NR 330 39 74 NR 49 19 16.2 6.8 Pv 4+ E5 12.6 12.1 32 NR 283 25 25 39 20 28 14 NR Pm 4+ E6 11.1 7.8 53 NR NR 11 NR NR NR NR 6.5 NR Pm 1+ F1 12.9 6.9 25 NR 915 38 254 67 NR 28 11.5 3.6 Pf 92 500 F2 14.1 13.3 53 NR 662 36 108 322 145 24 4.2 NR Pm 71 939 F3 12.6 20.5 8 NR 453 34 315 732 258 20 10.3 NR Pm 320 000 F4 13.8 12.1 73 NR 171 12 43 373 143 24 11.6 NR Pk 6471 F5 11.1 5.3 26 NR 143 12 46 NR NR 27 14.3 NR Pv 9866 F6 11 8.2 67 NR 132 14 234 61 36 20 16 NR Pm 4+ F7 12 11.2 60 NR 124 6 NR NR NR NR NR NR Pm 22 666 G1 15.8 19.5 49 123 131 11 NR NR NR NR NR NR Pk 22 400 G2 9.9 8.5 63 121 609 50 NR NR NR NR NR NR Pk 71 939 G3 13.2 12 159 118 326 15 32 37 24 31 12.7 NR Pf 3+ G4 13.1 7.6 44 123 481 33 36 122 57 18 12.8 NR Pm 1+ G5 14.3 6.4 76 128 120 9 38 21 14 NR 22.3 NR Pm 4+ G6 8.3 18 104 128 230 27 84 54 31 26 15 1.96 Pf ++++ Median 12.7 11 38.5 128 355 26.5 108 77 79.5 24 12.8 6.4 … … Blood culture results were available in 14 cases: 13 were negative at 3 days of incubation, and 1 (E6) grew Enterobacter cloacae. ++++ indicates >4,000 parasites/µL.

4 76 128 120 9 38 21 14 NR 22.3 NR Pm 4+ G6 8.3 18 104 128 230 27 84 54 31 26 15 1.96 Pf ++++ Median 12.7 11 38.5 128 355 26.5 108 77 79.5 24 12.8 6.4 … … Blood culture results were available in 14 cases: 13 were negative at 3 days of incubation, and 1 (E6) grew Enterobacter cloacae. ++++ indicates >4,000 parasites/µL. Abbreviations: Alb, albumin; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; Bili, serum bilirubin; creat, serum creatinine, Hb, plasma hemoglobin; HCO3, serum bicarbonate; Lac, serum lactate; Na, serum sodium; NR, not reported; Pf, Plasmodium falciparum; Pm, Plasmodium malariae; Pk, Plasmodium knowlesi; Plt, platelet count; Pv, Plasmodium vivax; Urea, serum urea; WBC, white blood cell count. a Plasmodium species by microscopy. Table 4. Severity Criteria on Presentation

Abbreviations: Alb, albumin; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; Bili, serum bilirubin; creat, serum creatinine, Hb, plasma hemoglobin; HCO3, serum bicarbonate; Lac, serum lactate; Na, serum sodium; NR, not reported; Pf, Plasmodium falciparum; Pm, Plasmodium malariae; Pk, Plasmodium knowlesi; Plt, platelet count; Pv, Plasmodium vivax; Urea, serum urea; WBC, white blood cell count. a Plasmodium species by microscopy. Table 4. Severity Criteria on Presentation Case Anemia AKI Hypoglycemia Acidosis Hyperparasitemia Jaundice Comaa Shock Bleeding Respiratory Distress Total A1 N Y NR NR Y Y N N N N 3 A2 N NR NR NR N Y N N N Y 2 A3 N NR NR NR Y Y N N N N 2 A4 N Y NR NR Y Y N N N N 3 B1 N Y Y Y Y Y NR Y NR Y 7 B2 N N N N Y Y NR N NR Y 3 C1 N NR NR NR Y NR N Y N Y 3 D1 N Y Y Y NR Y N Y N Y 6 D2 N Y N Y NR Y N Y N Y 5 D3 N Y Y Y NR Y N Y N Y 6 D4 N Y N N NR N N N N Y 2 D5 N N N N NR N N Y N Y 2 D6 N Y N N NR Y N N N Y 3 E1 N Y NR NR NR NR N Y NR Y 3 E2 N NR NR NR NR NR N N N N 0 E3 N Y NR Y NR Y N Y N Y 5 E4 N Y NR Y NR Y N N N Y 4 E5 N Y NR Y NR N N N N Y 3 E6 N NR NR Y N NR N N N N 1 F1 N Y NR Y N Y N N N N 3 F2 N Y Y Y Y Y N N N N 5 F3 N Y NR Y Y Y N N N Y 5 F4 N N NR Y N N Yb N N Y 3 F5 N N NR NR N Y N N N N 1 F6 N N NR N NR Y N Y N N 2 F7 N N NR NR Y NR N N N N 1 G1 N N NR NR N NR N Y N Y 3 G2 N Y NR NR Y NR N N N N 2 G3 N Y NR Y NR N N N N N 2 G4 N Y NR Y NR N N Y N Y 4 G5 N N Hyper N N N N N N N 0 G6 N Y Hyper Y Y Y N Y N Y 6 Frequency, No. (%) 0/32 (0) 19/27 (70) 4/11 (36) 15/21 (71) 11/18 (61) 18/25 (72) 1/30 (3) 12/32 (38) 0 (0) 19/32 (59) Definitions of severe Plasmodium knowlesi malaria criteria: severe anemia, hemoglobin <7.0 g/dL (adults) or <5.0 g/dL (children); AKI, creatinine >265 µmol/L; hypoglycemia, blood glucose <2.2 mmol/L; metabolic acidosis, bicarbonate <15 mmol/L or lactate >5 mmol/L; hyperparasitemia, parasite count >100 000 parasites/µL (or >2% infected red blood cells); jaundice, bilirubin >50 µmol/L, with parasitemia >20 000/µL and/or creatinine >132 µmol/L; coma, Glasgow Coma Scale (GCS) <11; shock, systolic blood pressure <80 mm Hg with cool peripheries or impaired capillary refill; significant abnormal bleeding; respiratory distress, oxygen saturation <92% with respiratory rate >30 breaths/minute.

in >50 µmol/L, with parasitemia >20 000/µL and/or creatinine >132 µmol/L; coma, Glasgow Coma Scale (GCS) <11; shock, systolic blood pressure <80 mm Hg with cool peripheries or impaired capillary refill; significant abnormal bleeding; respiratory distress, oxygen saturation <92% with respiratory rate >30 breaths/minute. Abbreviations: AKI, acute kidney injury; Hyper, hyperglycemia; N, no; NR, not reported; Y, yes. aNot reported to date in knowlesi malaria. bAlternative causes for reduced GCS not excluded. Case 1 (G1) A 32-year-old pregnant woman at 35 weeks’ gestation (G6P5) presented with reduced fetal movement, 14 days of fever, and 2 days of intermittent abdominal pain and dyspnea. She was hypotensive, tachycardic, hypoxic, and tachypneic. She had hyponatremia, thrombocytopenia, and acute kidney injury (AKI). She was intubated, ventilated, and given IV ceftriaxone, sodium bicarbonate, and ionotropic support. A chest radiograph showed diffuse interstitial infiltrates consistent with acute respiratory distress syndrome (ARDS). A blood film taken 4 hours after admission was reported as P. knowlesi, with 22 400 parasites/µL. Oral artemether-lumefantrine and doxycycline were given, and tertiary hospital transfer was arranged for IV artesunate; however, the patient had a cardiac arrest while awaiting transfer. Admission blood cultures were negative.

ood film taken 4 hours after admission was reported as P. knowlesi, with 22 400 parasites/µL. Oral artemether-lumefantrine and doxycycline were given, and tertiary hospital transfer was arranged for IV artesunate; however, the patient had a cardiac arrest while awaiting transfer. Admission blood cultures were negative. Case 2 (G2) A 50-year-old male Indonesian palm-oil plantation worker presented to a district hospital with 1 week of fever, rigors, headache, epigastric pain, and diarrhea. Physical examination revealed hepatomegaly (3 cm), but was otherwise unremarkable. He had severe AKI, hyponatremia, and thrombocytopenia. A blood film was reported as P. knowlesi with 71 939 parasites/µL. Chest radiography showed generalized interstitial infiltrates. He was diagnosed with severe malaria and commenced on IV artesunate, and a tertiary hospital transfer was arranged; however, he arrested en route. This case has been previously documented [10].

lood film was reported as P. knowlesi with 71 939 parasites/µL. Chest radiography showed generalized interstitial infiltrates. He was diagnosed with severe malaria and commenced on IV artesunate, and a tertiary hospital transfer was arranged; however, he arrested en route. This case has been previously documented [10]. Case 3 (G3) A 37-year-old woman with a history of gestational hypertension presented to a district hospital with 4 days of fever, rigors, epigastric pain, dizziness, and vomiting. She was hypotensive, tachycardic, and had epigastric tenderness. The initial diagnosis was dyspepsia, and she received ranitidine, prochlorperazine, and fluid resuscitation. AKI was noted 2 hours after admission, and IV ceftriaxone was initiated for presumed sepsis. Twelve hours after hospitalization, she became tachypneic, with reduced consciousness (Glasgow Coma Scale reported as 9/15), and severe metabolic acidosis (arterial pH, 7.02; bicarbonate, 2.5 mEq/L). She underwent intubation, ventilation, and hemodialysis and received IV sodium bicarbonate and imipenem. The patient deteriorated further on day 2, with transaminitis (alanine aminotransferase [ALT] level, 426 U/L; aspartate aminotransferase [AST] level, 1481 U/L), metabolic acidosis, and coagulopathy (international normalized ratio [INR], 1.9; prothrombin time, 52 seconds) requiring fresh frozen plasma. The patient arrested 43 hours after admission. Blood films taken prior to death were reported as P. malariae with 2285 parasites/µL. It was later noted that an admission blood film had been reported as “P. falciparum 3+.” No antimalarial treatment had been given. Blood cultures were negative.

iring fresh frozen plasma. The patient arrested 43 hours after admission. Blood films taken prior to death were reported as P. malariae with 2285 parasites/µL. It was later noted that an admission blood film had been reported as “P. falciparum 3+.” No antimalarial treatment had been given. Blood cultures were negative. Case 4 (G4) A 32-year-old Filipino man presented with 5 days of fever, cough, and coryzal symptoms. He was tachycardic, but physical examination was otherwise unremarkable. He was given fluids and acetaminophen (paracetamol). A blood smear was reported as “P. malariae 1+” with AKI, hyponatremia, and thrombocytopenia also noted. Oral artemether-lumefantrine was given. Twenty-two hours after admission, the patient had hemoptysis with tachypnea and hypoxia. A chest radiograph showed generalized interstitial infiltrates. A diagnosis of severe P. malariae with ARDS was made and IV artesunate was initiated. After further hemoptysis, a bedside ultrasound showed pleural and pericardial effusions and noninvasive ventilation was initiated. At 48 hours, massive hemoptysis occurred. He required intensive care unit admission, intubation, ventilation, inotropic support, hemodialysis for metabolic acidosis and uremia, and red cell and fresh frozen plasma transfusions. Echocardiography (ECG) showed severe mitral stenosis. Admission blood cultures were negative. He died on day 4, with cause of death recorded as severe malaria with pulmonary hemorrhage and underlying mitral stenosis.

ort, hemodialysis for metabolic acidosis and uremia, and red cell and fresh frozen plasma transfusions. Echocardiography (ECG) showed severe mitral stenosis. Admission blood cultures were negative. He died on day 4, with cause of death recorded as severe malaria with pulmonary hemorrhage and underlying mitral stenosis. Case 5 (G5) A 42-year-old fisherman with morbid obesity, obstructive sleep apnea, and congestive cardiac failure was referred to a district hospital from a peripheral clinic with 9 days of fever, and 3 days of dyspnea, epigastric pain, and vomiting. The clinic blood film was reported as “complicated malaria with hyperparasitemia”; Plasmodium species was not specified. On admission he was tachycardic, hypotensive, and hypoxic. ECG showed atrial fibrillation at 160 beats per minute. He received IV artesunate, fluid resuscitation, and high-flow oxygen. He was hyponatremic, with AKI, hyperglycemia, and a compensated metabolic acidosis. A blood film was reported as “P. malariae 4+.” He required intubation, hemodialysis, IV insulin, digoxin, and inotropic support. Seven hours postadmission, ECG showed cardiac ischemia, and at 15 hours the patient arrested. Admission blood cultures were negative. Cause of death was recorded as (1) malaria with hyperparasitemia, and (2) decompensated cardiac failure, with likely underlying cardiomyopathy.

V insulin, digoxin, and inotropic support. Seven hours postadmission, ECG showed cardiac ischemia, and at 15 hours the patient arrested. Admission blood cultures were negative. Cause of death was recorded as (1) malaria with hyperparasitemia, and (2) decompensated cardiac failure, with likely underlying cardiomyopathy. Case 6 (G6) A 58-year-old Caucasian expatriate man with a history of ischemic heart disease, left bundle-branch block, hypertension, and paroxysmal atrial fibrillation presented to a private hospital with 9 days of fever, palpitations, and lethargy. He was hypotensive, hypoxic, and tachypneic. A blood smear was reported as “heavy infection, likely P. falciparum.” He was anemic, hyperbilirubinemic, and hyponatremic, with AKI and metabolic acidosis. He was commenced on ionotropic support and transferred to a tertiary public hospital for IV artesunate. There he also received ceftriaxone; hydrocortisone; insulin infusion for hyperglycemia; cardioversion for ventricular tachycardia; and, later, intubation, ventilation, and continuous venovenous hemofiltration. A blood film on day 1 was reported as P. knowlesi with 246 100 parasites/µL. On day 2, he had worsening metabolic acidosis (lactate, 11.7 mmol/L; pH, 7.13; bicarbonate, 10.4 mEq/L), coagulopathy (INR, 4.53), and transaminitis (AST, >4200 U/L; ALT, 1820 U/L), with a bilirubin of 247 μmol/L, and was anuric. He died on day 3, with cause of death recorded as severe knowlesi malaria with multiorgan failure.

, he had worsening metabolic acidosis (lactate, 11.7 mmol/L; pH, 7.13; bicarbonate, 10.4 mEq/L), coagulopathy (INR, 4.53), and transaminitis (AST, >4200 U/L; ALT, 1820 U/L), with a bilirubin of 247 μmol/L, and was anuric. He died on day 3, with cause of death recorded as severe knowlesi malaria with multiorgan failure. Systematic Review of P. knowlesi Fatalities Ten original research articles reporting P. knowlesi fatalities were identified (Figure 1). Thirty PCR-confirmed P. knowlesi deaths were reported: 19 from Sabah and 11 from Sarawak, Malaysia, all occurring during 2001–2014. Four of the Sarawak deaths were excluded from further review due to insufficient individual patient data [15]. Figure 1. Flow diagram of systematic review. aFour retrospective case series or studies [4, 9, 12, 14], 2 prospective observational studies [10, 11], 1 case-control study [15], 2 case reports [13, 16], and 1 review of autopsies [35]. bFour reported deaths were excluded from further review as sufficient individual patient data were not available [15]. cNineteen deaths occurred in Sabah and 7 in Sarawak, Malaysia, all during 2001–2014.

observational studies [10, 11], 1 case-control study [15], 2 case reports [13, 16], and 1 review of autopsies [35]. bFour reported deaths were excluded from further review as sufficient individual patient data were not available [15]. cNineteen deaths occurred in Sabah and 7 in Sarawak, Malaysia, all during 2001–2014. Demographic, clinical, and laboratory details for each case are summarized in Tables 1–3, with severity criteria shown in Table 4. Combining these 26 previously reported cases with the 2015–2017 series, median age was 56 (range, 23–84) years, and 18 (56%) were male. Female fatal cases were older than male fatal cases (median age, 62 vs 51 years, respectively), although this was not statistically significant. Median duration of fever was 6 (interquartile range, 4–7) days, with no difference between women and men. At presentation, 30 of 32 (94%) patients met the World Health Organization (WHO) criteria for severe malaria, although only 19 of these 30 (63%) were recognized as having severe malaria. Of those meeting severity criteria, the median number of criteria was 3 (range, 1–7), with the most frequent criteria being respiratory distress (n = 19/32 [59%]), jaundice (n = 18/25 [72%]), and severe AKI (n = 19/27 [70%]). Abdominal pain was reported in 17 of 26 (65%) cases. Decreased conscious state was reported on presentation in 1 case; however, alternative causes were not excluded [4]. Cardiovascular-metabolic comorbidities were a notable factor of previously reported cases as well as in the current series. Overall, hypertension was reported in 8 of 32 (25%) cases and stress hyperglycemia or diabetes mellitus in 12%.

ported on presentation in 1 case; however, alternative causes were not excluded [4]. Cardiovascular-metabolic comorbidities were a notable factor of previously reported cases as well as in the current series. Overall, hypertension was reported in 8 of 32 (25%) cases and stress hyperglycemia or diabetes mellitus in 12%. Table 2. Clinical Features on Presentation

ported on presentation in 1 case; however, alternative causes were not excluded [4]. Cardiovascular-metabolic comorbidities were a notable factor of previously reported cases as well as in the current series. Overall, hypertension was reported in 8 of 32 (25%) cases and stress hyperglycemia or diabetes mellitus in 12%. Table 2. Clinical Features on Presentation Case BP, mm Hg HR, Beats/Min O2, % RR, Breaths/Min Temperature, °C Abdominal Paina Comorbidities or Pregnancy A1 120/90 88 NR NR 36.8 Y … A2 124/66 132 NR NR 38.0 Y … A3 81/51 84 NR NR 36.0 Y … A4 132/67 84 NR NR 36.0 Y … B1 80 sys NR NR NR NR NR … B2 NR NR NR NR NR NR HTN C1 U NR NR NR NR Y … D1 126/70 130 85 NR 36.8 NR IHD D2 136/57 101 56 NR 38.0 N NR D3 100/50 110 90 NR 36.7 Y NR D4 120/69 94 NR NR 38.5 N NR D5 90/50 130 89 NR 37.5 NR NR D6 80/50 120 90 NR 37.9 Y NR E1 75/49 127 75 NR 39.4 NR HTN, COPD E2 117/73 58 92 NR 36.8 N HTN, T2D E3 70/40 110 90 NR 37.6 Y … E4 83/51 89 60 NR 37.5 N … E5 112/51 113 88 NR 36.7 NR … E6 131/87 110 85 NR 37.8 Y … F1 129/72 108 97 24 37.4 Y … F2 127/87 108 96 38 37.0 Y HTN F3 112/79 124 88 26 36.8 Y HTN F4 85/60 150 81 25 36.2 N … F5 193/96 129 98 22 39.0 N HTN, T2D F6 80/49 72 100 20 37.7 N TB F7 116/71 111 96 22 39.9 N HTN G1 69/50 138 71 46 37.0 Y Pregnancy G2 106/64 80 96 18 36.8 Y … G3 96/36 104 100 16 36.6 Y … G4 U 126 98b 20 36.3 N Severe MR, TR G5 105/64 129 98 26 37.6 Y Morbid obesity, CCF, OSA G6 78/45 86 88 27 39.7 Y IHD, HTN, PAF Median … 110 90 24 37.4 … … Abbreviations: BP, blood pressure; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; HR, heart rate; HTN, hypertension; IHD, ischemic heart disease; MR, mitral valve regurgitation; N, no; NR, not reported; O2, oxygen saturation; OSA, obstructive sleep apnea; PAF, paroxysmal atrial fibrillation; RR, respiratory rate; Sys, systolic; T2D, type 2 diabetes mellitus; TB, tuberculosis; TR, tricuspid valve regurgitation; U, unrecordable; Y, yes.

HD, ischemic heart disease; MR, mitral valve regurgitation; N, no; NR, not reported; O2, oxygen saturation; OSA, obstructive sleep apnea; PAF, paroxysmal atrial fibrillation; RR, respiratory rate; Sys, systolic; T2D, type 2 diabetes mellitus; TB, tuberculosis; TR, tricuspid valve regurgitation; U, unrecordable; Y, yes. aPreviously demonstrated as a risk factor for severe malaria. bFifteen liters/minute high-flow oxygen. Among all fatal cases, species diagnosis on admission microscopy was incorrect in 26 of 29 (90%), including 20 (69%) diagnosed as P. malariae, 4 (14%) as P. falciparum, and 2 (7%) as Plasmodium vivax. Thrombocytopenia was universal on presentation, as was elevated creatinine (Table 3). All patients with an available serum sodium result were hyponatremic. No patient had severe anemia at presentation. Intravenous antimalarial treatment was administered on presentation in 17 of 21 (81%) cases with severe malaria on presentation. Median time to death was 41 (range, 1–316) hours.

ted creatinine (Table 3). All patients with an available serum sodium result were hyponatremic. No patient had severe anemia at presentation. Intravenous antimalarial treatment was administered on presentation in 17 of 21 (81%) cases with severe malaria on presentation. Median time to death was 41 (range, 1–316) hours. Case Fatality Rates The P. knowlesi CFR in Sabah was 1.70/1000 (95% confidence interval [CI], 1.66–1.75; 6/3524) during 2015–2017. For women this was 3.6/1000 (95% CI, 3.4–3.8; 2/558), compared to 1.4/1000 (95% CI 1.3–1.4; 4/2966) for men (P = .24). Incorporating previously reported data from 2010 to 2014 (6 deaths among 783 P. knowlesi cases in women; 7 deaths among 3443 cases in men) [4], the overall CFR during 2010–2017 was 2.45/1000 cases (95% CI, 2.42–2.49; 19/7750): 6.0/1000 (95% CI 5.9–6.1; 8/1341) for women and 1.7/1000 (95% CI, 1.7–1.8; 11/6409) for men (P = .01). The higher CFR in women remained significant after adjusting for age (odds ratio [OR], 2.6 [95% CI, 1.0–6.7]; P = .043). The CFR for patients aged ≥45 years was 5.8/1000 (95% CI, 5.7–5.9; 13/2228) compared to 1.1/1000 (95% CI, 1.0–1.1; 6/5514) for those aged <45 years (P < .001). Age ≥45 years remained a significant risk factor for death after adjusting for sex (OR, 4.7 [95% CI, 1.8–12.5]; P = .002).

R], 2.6 [95% CI, 1.0–6.7]; P = .043). The CFR for patients aged ≥45 years was 5.8/1000 (95% CI, 5.7–5.9; 13/2228) compared to 1.1/1000 (95% CI, 1.0–1.1; 6/5514) for those aged <45 years (P < .001). Age ≥45 years remained a significant risk factor for death after adjusting for sex (OR, 4.7 [95% CI, 1.8–12.5]; P = .002). DISCUSSION We describe 6 malaria deaths in Sabah during 2015–2017, and review 26 previously reported P. knowlesi deaths. Plasmodium knowlesi accounted for all recent malaria deaths in Sabah, in contrast to previous reports during 2010–2014 where 13 of 29 (44%) deaths were attributed to P. knowlesi [4, 12]. This increase in proportion of fatal cases attributed to P. knowlesi is consistent with the decline of falciparum and vivax malaria in Sabah, and the ongoing increase in cases of P. knowlesi [4, 18]. The fact that the total number of P. knowlesi deaths per year has remained relatively stable despite this increasing incidence is consistent with previously reported declining CFRs in Sabah [4], likely reflecting ongoing increases in awareness and improved management of severe knowlesi malaria.

of P. knowlesi [4, 18]. The fact that the total number of P. knowlesi deaths per year has remained relatively stable despite this increasing incidence is consistent with previously reported declining CFRs in Sabah [4], likely reflecting ongoing increases in awareness and improved management of severe knowlesi malaria. It is notable that all reported fatal cases were adults. This is consistent with the absence of severe knowlesi malaria in children [10, 19], and is in marked contrast to the predominance of severe and fatal malaria from P. falciparum and P. vivax in the pediatric age group [20]. Older age is a known risk factor for severe knowlesi malaria [8, 10, 17], and in this study age ≥45 years was associated with a 5-fold increase in risk of death. It was also notable that nearly half of all reported fatal cases were women. This contrasts with the predominance of men in studies of nonfatal knowlesi malaria, with men consistently accounting for 75%–80% of cases [21, 22]. We previously hypothesized that the higher CFR in women with knowlesi malaria was due in part to their older median age [4]. However, here we now demonstrate that women are more than twice as likely to die from knowlesi malaria even after adjusting for age. There was no difference in parasitemias between male and female fatal cases, nor any difference in fever duration, suggesting that the higher mortality was not due to delays in health-seeking behavior. A higher risk of death in females has also been noted in other severe infections [23–25]. Further studies are required to investigate the pathogenic or other factors that may account for this increased risk [24].

e in fever duration, suggesting that the higher mortality was not due to delays in health-seeking behavior. A higher risk of death in females has also been noted in other severe infections [23–25]. Further studies are required to investigate the pathogenic or other factors that may account for this increased risk [24]. Respiratory distress and AKI were the most common severity criteria on presentation in fatal cases. Abdominal pain, previously reported as a risk factor for severe knowlesi malaria [10], was present in 53% of all cases. Potential explanations include gut ischemia from microvascular accumulation of parasitized red cells and/or gastric ulceration [14]. Thrombocytopenia was universal among fatal cases. This may relate to the higher proportion of platelet binding to infected red cells found in P. knowlesi compared with other species [26]. Hyponatremia, a known metabolic abnormality in severe falciparum and knowlesi malaria [8, 10, 27], was present in all fatal cases. Hypoglycemia occurred in 15% of previously reported fatal cases; however, in this series, 2 cases of hyperglycemia associated with death also occurred. This may relate to the older age of knowlesi-infected patients with severe malaria [8, 17], and rising prevalence of metabolic syndrome with age.

nt in all fatal cases. Hypoglycemia occurred in 15% of previously reported fatal cases; however, in this series, 2 cases of hyperglycemia associated with death also occurred. This may relate to the older age of knowlesi-infected patients with severe malaria [8, 17], and rising prevalence of metabolic syndrome with age. Comorbidities are a notable feature in fatal knowlesi malaria. Half of the newly described cases had underlying cardiovascular-metabolic disease (including severe mitral stenosis, heart failure, and morbid obesity), and hypertension and hyperglycemia or diabetes mellitus were also common in the previously reported cases. Cardiovascular disease and metabolic syndrome are known to be associated with increased systemic inflammation, endothelial activation, and microvascular dysfunction [28], all features of severe knowlesi malaria [17]. It is thus plausible that cardiovascular-metabolic disease would increase the risk of severe knowlesi malaria, as has been reported in falciparum malaria [29].

to be associated with increased systemic inflammation, endothelial activation, and microvascular dysfunction [28], all features of severe knowlesi malaria [17]. It is thus plausible that cardiovascular-metabolic disease would increase the risk of severe knowlesi malaria, as has been reported in falciparum malaria [29]. This series includes the first report of fatal knowlesi malaria in pregnancy, occurring at 35 weeks’ gestation. Plasmodium knowlesi is relatively rare in pregnancy, with only 5 cases reported previously [9, 30]. Pregnancy is known to increase risk of severe maternal disease in falciparum malaria [20]. Of the 5 previously described cases of P. knowlesi in pregnancy, 1 had severe malaria with intrauterine death, 2 had moderate anemia, and 1 delivered a preterm low-birth-weight infant [9, 30]. With the current fatal case, 2 of 6 (33%) reported cases of P. knowlesi in pregnancy have resulted in severe maternal malaria and fetal death. Prospective studies are required to further evaluate the true risks and consequences of knowlesi malaria in pregnancy.

and 1 delivered a preterm low-birth-weight infant [9, 30]. With the current fatal case, 2 of 6 (33%) reported cases of P. knowlesi in pregnancy have resulted in severe maternal malaria and fetal death. Prospective studies are required to further evaluate the true risks and consequences of knowlesi malaria in pregnancy. Several health-system issues contributed to deaths in this newly reported series. In 3 cases, the diagnosis of severe malaria was delayed despite the presence of compatible clinical features, and in another 2, IV artesunate was not available. Half of the cases were non-Malaysian citizens, which, together with the long duration of fever in this series (median, 8 days), suggests possible barriers to accessing healthcare. These findings highlight the need to evaluate strategies to improve healthcare access in endemic areas, in addition to ensuring availability of appropriate antimalarials at all facilities. In the combined analysis, 90% of fatal cases had an alternative Plasmodium species diagnosed on admission microscopy. This is consistent with the inability of routine microscopy to reliably distinguish P. knowlesi from other species [31], which, combined with the poor sensitivity and specificity of available rapid diagnostic tests [32, 33], highlights the importance of a unified treatment strategy of IV artesunate for severe malaria from any species [20, 34].

he inability of routine microscopy to reliably distinguish P. knowlesi from other species [31], which, combined with the poor sensitivity and specificity of available rapid diagnostic tests [32, 33], highlights the importance of a unified treatment strategy of IV artesunate for severe malaria from any species [20, 34]. A limitation of this study was the retrospective nature of the case series, resulting in either incomplete or unvalidated data. In particular, parasite counts were surprisingly low in some cases (G4 and G3), and it is possible that blood films may have been misreported. Second, the Department of Health data used to calculate CFRs did not include parasite counts, and hence the contribution of parasitemia to age and sex as risk factors for death could not be evaluated. Plasmodium knowlesi parasitemia is known to increase with age; however, age has been shown to be an independent risk factor for severe knowlesi malaria [10, 17], and hence would be expected to be an independent risk factor for death. In the largest prospective studies conducted to date [10, 17], an independent association between parasitemia and sex was not found; thus, a difference in parasitemia is unlikely to account for the increased CFR in women. Finally, it is possible that not all cases of P. knowlesi are notified, so the CFRs reported in this manuscript may overestimate the true CFRs.

to date [10, 17], an independent association between parasitemia and sex was not found; thus, a difference in parasitemia is unlikely to account for the increased CFR in women. Finally, it is possible that not all cases of P. knowlesi are notified, so the CFRs reported in this manuscript may overestimate the true CFRs. In conclusion, this review highlights the potential for poor outcomes from knowlesi malaria, and identifies female sex, age ≥45 years, and comorbidities as important associated factors. With the near-elimination of falciparum and vivax malaria in Sabah, Malaysia, health systems must maintain efforts to promptly diagnose and treat patients with knowlesi malaria to avoid fatal outcomes, particularly in these at-risk groups. This will require ongoing surveillance and efforts to increase awareness among communities and health providers, as well as improving access to healthcare and ensuring availability of appropriate antimalarials at all health facilities. Notes Acknowledgments. The authors acknowledge the help of the medical records departments at the relevant facilitates for facilitating access to patient case notes; the Sabah Department of Health for providing malaria notification data; and the Director-General, Ministry of Health, Malaysia, for permission to publish the data. The authors thank Joseph Benedict, Clarice James, and Danshy Alaza at the Infectious Disease Society, Kota Kinabalu, Sabah, for assistance with data collection, and Tsin Wen Yeo for providing additional unpublished data on cases D1–D6.

Director-General, Ministry of Health, Malaysia, for permission to publish the data. The authors thank Joseph Benedict, Clarice James, and Danshy Alaza at the Infectious Disease Society, Kota Kinabalu, Sabah, for assistance with data collection, and Tsin Wen Yeo for providing additional unpublished data on cases D1–D6. Financial support. This work was supported by the Australian National Health and Medical Research Council (fellowships to N. M. A., B. E. B., and M. J. G.), and Charles Darwin University Prestigious International Research Tuition Scholarship and University Postgraduate Research Scholarship to D. J. C. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.